Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Short term Debt for 8 consecutive years, with $199.7 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $199.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $199.7 million for FY2025, N/A changed from the prior year.
  • Short term Debt hit $199.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $199.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $199.8 million in Q1 2024 to a low of $112.9 million in Q2 2021.
  • Historically, Short term Debt has averaged $169.2 million across 5 years, with a median of $199.3 million in 2023.